Business
Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma
Published Recently in the Journal of the American Academy of Dermatology FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\n Published Recently in the Journal of the American Academy of Dermatology\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of development and validation data for DecisionDx®-SCC, its prognostic test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC). The test is expected to be launched commercially in the second half of 2020.\n\n\nThe article titled, “Validation of a 40-Gene Expression Profile Test to Predict Metastatic Risk in Localized High-Risk Cutaneous Squamous Cell Carcinoma,” was published in the Journal of the American Academy of Dermatology (JAAD).\n\n\nThe study results demonstrate that DecisionDx-SCC is an independent predictor of metastatic risk that can complement current cancer risk-factor staging systems for patients with high-risk SCC.\n\n\n“As clinicians, we struggle with treatment decisions for patients with high-risk cutaneous squamous cell carcinoma due to the limitations of clinicopathologic based staging systems,” said first author, Ashley Wysong, M.D., University of Nebraska Medical Center, Omaha NE. “Validation of the DecisionDx-SCC test demonstrates significant progress in this area by integrating tumor-specific genetic information into clinical decision making. Having better prognostic information helps us to identify patients as low risk by tumor biology and manage them more conservatively with clinical surveillance, as well as provides us with data to help guide implementation of adjuvant interventions and clinical trial recommendations for those identified as high risk.”\n\n\nDisease and Study Background\n\n\n\nApproximately 1 million patients are diagnosed with SCC of the skin in the U.S. each year, and the incidence continues to grow; approximately 80% can be cured surgically, but it is estimated that approximately 200,000 patients are diagnosed with high-risk SCC.\n\n\nSCC National Comprehensive Cancer Network (NCCN) guidelines define treatment pathways based on risk of local recurrence or metastasis. For SCC, there are two clinicopathologically defined categories: low risk and high risk. NCCN defines high risk as SCC patients with one or more of several high-risk clinicopathologic feature...